Belvedere Trading’s Biocept, Inc. BIOC Stock Holding History

Belvedere Trading’s Portfolio BIOC Stock Details BIOC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-2,515	Closed	-$384K	–	477
2021 Q1	$384K	Buy	+2,515	New	+$457K	0.03%	114

Other funds holding BIOC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

HSA

Hussman Strategic Advisors Ellicott City, Maryland $463M AUM 16% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Belvedere Trading's BIOC Position: Q2 2021 in Review

Belvedere Trading sold out of Biocept, Inc. (BIOC) in Q2 2021, closing a stake of 2,515 shares — an estimated $384K sold.

Belvedere Trading first reported a position in BIOC in Q1 2021 and held it in 1 quarter. The position peaked at $384K in Q1 2021. 21 funds tracked by Wall St. Rank hold BIOC as of Q2 2021.

Belvedere Trading reported no remaining Biocept, Inc. position as of Q2 2021 after selling out during the quarter.
Belvedere Trading sold 2,515 Biocept, Inc. shares in Q2 2021, an estimated $384K.
Belvedere Trading first reported a position in Biocept, Inc. in Q1 2021 and held it in 1 quarter.
Belvedere Trading's Biocept, Inc. position peaked at $384K in Q1 2021.
21 funds tracked by Wall St. Rank held Biocept, Inc. as of Q2 2021.

Based on Belvedere Trading's 13F filing for Q2 2021, filed 23 Jul 2021.